763114-22-3

Basic information

• Product Name: Benzonitrile, 3-(2,3-dihydro-1,3-dioxo-1H-inden-2-yl)-
• CAS NO: 763114-22-3
• Molecular Formula: C16H9NO2
• Molecular Weight: 247.253
• Mol File: 763114-22-3.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: Benzonitrile, 3-(2,3-dihydro-1,3-dioxo-1H-inden-2-yl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzonitrile, 3-(2,3-dihydro-1,3-dioxo-1H-inden-2-yl)-(763114-22-3)
• EPA Substance Registry System: Benzonitrile, 3-(2,3-dihydro-1,3-dioxo-1H-inden-2-yl)-(763114-22-3)

Safety Data

• Hazardous Substances Data: 763114-22-3(Hazardous Substances Data)

Upstream product

• 87-41-2 2-benzofuran-1(3H)-one 
• 24964-64-5 3-Cyanobenzaldehyde 
• 105-37-3 Ethyl propionate 

Downstream Products

• 420846-72-6 3-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoic acid 
• 763114-23-4 3-(1,3-dioxoindan-2-yl)benzoic acid 
• 763114-24-5 2-[2-(3-carboxyphenyl)acetyl]benzoic acid 

Relevant articles and documents

HETEROCYCLIC-IMIDAZOLE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF

The present invention relates to a heterocyclic-imidazole derivative, a preparation method therefor, and a medical use thereof, and particularly to a new heterocyclic-imidazole derivative of general Formula (I), a preparation method therefor, a pharmaceutical composition comprising the same, and use thereof as a therapeutic agent, particularly as a poly(ADP-ribose)polymerase (PARP) inhibitor.

4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl] -2H-phthalazin-1-one: A novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1

Poly(ADP-ribose) polymerase activation is an immediate cellular response to metabolic-, chemical-, or ionizing radiation-induced DNA damage and represents a new target for cancer therapy. In this article, we disclose a novel series of substituted 4-benzyl-2H-phthalazin-1-ones that possess high inhibitory enzyme and cellular potency for both PARP-1 and PARP-2. Optimized compounds from the series also demonstrate good pharmacokinetic profiles, oral bioavailability, and activity in vivo in an SW620 colorectal cancer xenograft model. 4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl] -2H-phthalazin-1-one (KU-0059436, AZD2281) 47 is a single digit nanomolar inhibitor of both PARP-1 and PARP-2 that shows standalone activity against BRCA1-deficient breast cancer cell lines. Compound 47 is currently undergoing clinical development for the treatment of BRCA1- and BRCA2-defective cancers.

PHTHALAZINONE DERIVATIVES

Compounds of the formula (I): wherein A and B together represent an optionally substituted, fused aromatic ring; X can be NRX or CRXRY; if X NRX then n is 1 or 2 and if X = CRXRY then n is 1; RX is selected from the group consisting of H, optionally substituted C1-20 alkyl, C5-20 aryl, C3-20 heterocyclyl, amido, thioamido, ester, acyl, and sulfonyl groups; RY is selected from H, hydroxy, amino; or RX and RY may together form a spiro-C3-7 cycloalkyl or heterocyclyl group; RC1 and RC2 are both hydrogen, or when X is CRX RY, RC1, RC2, RX and RY, together with the carbon atoms to which they are attached, may form an optionally substituted fused aromatic ring; and R1 is selected from H and halo.